These routines frequently include sophisticated products designed for adults, containing ingredients meant to fight wrinkles or boost luminosity. Children’s skin is still developing and more sensitive, so such products may cause irritation, dryness, or disrupt the natural skin barrier over time. Pediatric experts note that young skin needs only gentle cleansing and basic moisturizing, not complex regimens with active chemicals.

Social media amplifies the trend, with videos of even preschoolers applying makeup and skincare while narrating their day. Parents should monitor content exposure and choose age-appropriate products labeled for children. Consulting a dermatologist or pediatrician helps families select safe options and avoid unnecessary treatments.

Teaching kids healthy skin habits early supports long-term well-being without the pressure of flawless appearances pushed online.

Despite these early successes, advancing DFMO for BABS faces significant hurdles due to the disease’s rarity, which complicates patient recruitment, awareness, and large-scale clinical trials. Regulatory complexities and the need for robust preclinical data have stalled progress, with the FDA urging formal trials but key challenges like defining endpoints persisting. A new partnership with Every Cure, a nonprofit biotech organization dedicated to drug repurposing, is poised to accelerate momentum. Every Cure is supporting preclinical studies, retrospective analyses, regulatory navigation, and awareness campaigns among physicians and rare disease networks to ensure undiagnosed children are identified and treated. As noted by Every Cure’s co-founder David Fajgenbaum, MD, this collaboration aims to bridge evidence gaps and facilitate broader access. With preclinical work slated for next year, this initiative highlights the value of repurposing existing drugs for orphan diseases, offering hope for personalized therapies in pediatric genetics. For Indian doctors managing rare pediatric cases, this underscores the importance of genetic screening for ODC1 mutations and considering off-label uses of approved drugs like DFMO, potentially in collaboration with global networks to overcome similar barriers in resource-limited settings.